Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 03 2021
11 03 2021
Historique:
received:
21
07
2020
accepted:
18
02
2021
entrez:
12
3
2021
pubmed:
13
3
2021
medline:
15
12
2021
Statut:
epublish
Résumé
OATP1B3 is expressed de novo in primary prostate cancer tissue and to a greater degree in prostate cancer metastases. Gadoxetate disodium is a substrate of OATP1B3, and its uptake has been shown to correlate with OATP1B3 expression in other cancers. We aimed to evaluate use of gadoxetate disodium to image prostate cancer and to track its utility as a biomarker. A single center open-label non-randomized pilot study recruited men with (1) localized, and (2) metastatic castration resistant prostate cancer (mCRPC). Gadoxetate disodium-enhanced MRI was performed at four timepoints post-injection. The Wilcoxon signed rank test was used to compare MRI contrast enhancement ratio (CER) pre-injection and post-injection. OATP1B3 expression was evaluated via immunohistochemistry (IHC) and a pharmacogenomic analysis of OATP1B3, NCTP and OATP1B1 was conducted. The mCRPC subgroup (n = 9) demonstrated significant enhancement compared to pre-contrast images at 20-, 40- and 60-min timepoints (p < 0.0078). The localized cancer subgroup (n = 11) demonstrated earlier enhancement compared to the mCRPC group, but no retention over time (p > 0.05). OATP1B3 expression on IHC trended higher contrast enhancement between 20-40 min (p ≤ 0.064) and was associated with contrast enhancement at 60 min (p = 0.0422). OATP1B1 haplotype, with N130D and V174A substitutions, impacted enhancement at 40-60 min (p ≤ 0.038). mCRPC lesions demonstrate enhancement after injection of gadoxetate disodium on MRI and retention over 60 min. As inter-individual variability in OATP1B3 expression and function has both predictive and prognostic significance, gadoxetate disodium has potential as a biomarker in prostate cancer.
Identifiants
pubmed: 33707581
doi: 10.1038/s41598-021-84960-w
pii: 10.1038/s41598-021-84960-w
pmc: PMC7952731
doi:
Substances chimiques
SLCO1B3 protein, human
0
Solute Carrier Organic Anion Transporter Family Member 1B3
0
gadolinium ethoxybenzyl DTPA
0
Gadolinium DTPA
K2I13DR72L
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
5662Subventions
Organisme : Intramural NIH HHS
ID : ZIA BC010547
Pays : United States
Organisme : Intramural Research Program of the National Institutes of Health, National Cancer Institute, Bethesda, MD, US.
ID : ZIA BC 010547
Références
Mostaghel, E. A. et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67(10), 5033–5041 (2007).
doi: 10.1158/0008-5472.CAN-06-3332
Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68(11), 4447–4454 (2008).
doi: 10.1158/0008-5472.CAN-08-0249
Obaidat, A., Roth, M. & Hagenbuch, B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol. 52, 135–151 (2012).
doi: 10.1146/annurev-pharmtox-010510-100556
Pressler, H., Sissung, T. M., Venzon, D., Price, D. K. & Figg, W. D. Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS ONE 6(5), e20372 (2011).
doi: 10.1371/journal.pone.0020372
Sissung, T. M. et al. Differential expression of OATP1B3 mediates unconjugated testosterone influx. Mol Cancer Res. 15(8), 1096–1105 (2017).
doi: 10.1158/1541-7786.MCR-16-0477
Hamada, A. et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 14(11), 3312–3318 (2008).
doi: 10.1158/1078-0432.CCR-07-4118
Wright, J. L. et al. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol. Biomark. Prev. 20(4), 619–627 (2011).
doi: 10.1158/1055-9965.EPI-10-1023
Alam, K., Farasyn, T., Ding, K. & Yue, W. Characterization of liver- and cancer-type-organic anion transporting polypeptide (OATP) 1B3 messenger RNA expression in normal and cancerous human tissues. Drug Metab. Lett. 12(1), 24–32 (2018).
doi: 10.2174/1872312812666180326110146
Yang, M. et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 29(18), 2565–2573 (2011).
doi: 10.1200/JCO.2010.31.2405
Sharifi, N. et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int. 102(5), 617–621 (2008).
doi: 10.1111/j.1464-410X.2008.07629.x
Mostaghel, E. A. et al. Association of tissue abiraterone levels and SLCO genotype with intraprostatic steroids and pathologic response in men with high-risk localized prostate cancer. Clin. Cancer Res. 23(16), 4592–4601 (2017).
doi: 10.1158/1078-0432.CCR-16-2245
de Morree, E. S. et al. Loss of SLCO1B3 drives taxane resistance in prostate cancer. Br. J. Cancer. 115(6), 674–681 (2016).
doi: 10.1038/bjc.2016.251
Gennaro, K. H., Porter, K. K., Gordetsky, J. B., Galgano, S. J. & Rais-Bahrami, S. Imaging as a personalized biomarker for prostate cancer risk stratification. Diagnostics (Basel). 8(4), 80 (2018).
doi: 10.3390/diagnostics8040080
Eovist FDA Label. In: FDA, editor. 2010.
Scharitzer, M. et al. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur. Radiol. 23(8), 2187–2196 (2013).
doi: 10.1007/s00330-013-2824-z
Leonhardt, M. et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab. Dispos. 38(7), 1024–1028 (2010).
doi: 10.1124/dmd.110.032862
Narita, M. et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J. Gastroenterol. 44(7), 793–798 (2009).
doi: 10.1007/s00535-009-0056-4
Ueno, A. et al. OATP1B3 expression is strongly associated with Wnt/beta-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J. Hepatol. 61(5), 1080–1087 (2014).
doi: 10.1016/j.jhep.2014.06.008
Nassif, A. et al. Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology 264(3), 741–750 (2012).
doi: 10.1148/radiol.12112061
Okubo, H. et al. Polymorphisms in the organic anion transporting polypeptide genes influence liver parenchymal enhancement in gadoxetic acid-enhanced MRI. Pharmacogenomics 14(13), 1573–1582 (2013).
doi: 10.2217/pgs.13.132
Park, S. H. et al. Aberrant expression of OATP1B3 in colorectal cancer liver metastases and its clinical implication on gadoxetic acid-enhanced MRI. Oncotarget. 8(41), 71012–71023 (2017).
doi: 10.18632/oncotarget.20295
Sissung, T. M. et al. Comparison of eight technologies to determine genotype at the UGT1A1 (TA)n repeat polymorphism: potential clinical consequences of genotyping errors?. Int. J. Mol. Sci. 21(3), 896 (2020).
doi: 10.3390/ijms21030896
Smith, N. F. et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther. 81(1), 76–82 (2007).
doi: 10.1038/sj.clpt.6100011
Thakkar, N. et al. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol. Pharm. 10(1), 406–416 (2013).
doi: 10.1021/mp3005353